UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
People with established cardiovascular disease need secondary prevention that addresses
multiple risk factors. Complexity & cost confer particularly difficult barriers to uptake of
treatment; recovery from a stroke or heart attack typically necessitates multiple drugs for
cholesterol, blood pressure and platelet function. A low-cost, fixed-dose, once-daily
combination polypill, the Red Heart Pill, has been formulated by Dr Reddy's Laboratories.
UMPIRE will evaluate whether provision of this polypill compared with usual medications
improves adherence and clinical outcomes among high-risk patients in Europe and India. The
results will be used to develop recommendations for equitable access.
Phase:
Phase 3
Details
Lead Sponsor:
Imperial College London
Collaborators:
Dr. Reddy's Laboratories Limited European Commission Imperial College Healthcare NHS Trust Public Health Foundation of India Royal College of Surgeons, Ireland The George Institute UMC Utrecht